Literature DB >> 31486038

Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.

Dipongkor Saha1,2, Samuel D Rabkin3.   

Abstract

Immunohistochemistry (IHC) is an integral laboratory staining technique, which is used for the detection of immune cells in mouse/human tissues or tumors. Oncolytic herpes simplex virus (oHSV) treatment or virotherapy of solid tumors results in antitumor immune responses and infiltration of a variety of immune cells into the tumor. Here, we describe a step-by-step chromogen/substrate-based single- and dual-color IHC protocol to stain immune cells in formalin-fixed, paraffin-embedded mouse glioblastoma (GBM) brain tumor sections after oHSV virotherapy. Tumor sections are deparaffinized with xylene, then gradually rehydrated using ethanol, followed by heat-mediated antigen retrieval using appropriate buffers. Tumor sections are incubated with primary antibodies, which detect a specific immune cell antigen, then incubated with peroxidase- or phosphatase-labeled secondary antibodies, followed by incubation with a color-producing substrate and color visualization (of immune cells) by light microscopy. The protocol described herein is also applicable to detect immune cells in other mouse and human tumors or organs after other forms of immunotherapy.

Entities:  

Keywords:  Antigen retrieval; Antigen–antibody reaction; Dual-color immunohistochemistry; Immune cells; Immunohistochemistry; Oncolytic herpes simplex virus; Substrate-based immunohistochemistry; Virotherapy

Year:  2020        PMID: 31486038      PMCID: PMC6827428          DOI: 10.1007/978-1-4939-9794-7_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Immunofluorescence Staining.

Authors:  Julie G Donaldson
Journal:  Curr Protoc Cell Biol       Date:  2015-12-01

Review 2.  Technical aspects of immunohistochemistry.

Authors:  J A Ramos-Vara
Journal:  Vet Pathol       Date:  2005-07       Impact factor: 2.221

3.  Immunohistochemistry.

Authors:  Marsha Goldstein; Simon Watkins
Journal:  Curr Protoc Mol Biol       Date:  2008-01

Review 4.  Rodent immunohistochemistry: pitfalls and troubleshooting.

Authors:  J M Ward; J E Rehg
Journal:  Vet Pathol       Date:  2013-09-27       Impact factor: 2.221

Review 5.  Oncolytic herpes simplex virus interactions with the host immune system.

Authors:  Dipongkor Saha; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  Curr Opin Virol       Date:  2016-08-03       Impact factor: 7.090

6.  Immunohistochemistry.

Authors:  Florence M Hofman; Clive R Taylor
Journal:  Curr Protoc Immunol       Date:  2013-11-18

7.  Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Authors:  Dipongkor Saha; Hiroaki Wakimoto; Cole W Peters; Slawomir J Antoszczyk; Samuel D Rabkin; Robert L Martuza
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

8.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Authors:  Dipongkor Saha; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

9.  EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Authors:  Dipongkor Saha; Seemin S Ahmed; Samuel D Rabkin
Journal:  Drugs Future       Date:  2015       Impact factor: 0.148

  9 in total
  8 in total

1.  Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice.

Authors:  David K Meyerholz; Mariah R Leidinger; J Adam Goeken; Thomas R Businga; Allison Akers; Sebastian Vizuett; Courtney A Kaemmer; Jordan L Kohlmeyer; Rebecca D Dodd; Dawn E Quelle
Journal:  BMC Res Notes       Date:  2022-06-25

2.  LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.

Authors:  Weidong Xu; Yuefeng Yang; Zebin Hu; Maria Head; Kathy A Mangold; Megan Sullivan; Edward Wang; Poornima Saha; Kamalakar Gulukota; Donald L Helseth; Theresa Guise; Bellur S Prabhkar; Karen Kaul; Hans Schreiber; Prem Seth
Journal:  Hum Gene Ther       Date:  2020-06-12       Impact factor: 5.695

3.  The long non-coding RNA T cell leukemia homeobox 1 neighbor enhances signal transducer and activator of transcription 5A phosphorylation to promote colon cancer cell invasion, migration, and metastasis.

Authors:  Guanyang Chen; Dongbo Lian; Lei Zhao; Zheng Wang; Qiqige Wuyun; Nengwei Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.

Authors:  Dipongkor Saha; Samuel D Rabkin; Robert L Martuza
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

5.  Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.

Authors:  Ming Li; Guoping Li; Juri Kiyokawa; Zain Tirmizi; Leland G Richardson; Jianfang Ning; Saumya Das; Robert L Martuza; Anat Stemmer-Rachamimov; Samuel D Rabkin; Hiroaki Wakimoto
Journal:  Acta Neuropathol Commun       Date:  2020-12-11       Impact factor: 7.801

6.  The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.

Authors:  Moritz Klawitter; Ali El-Ayoubi; Jasmin Buch; Jakob Rüttinger; Maximilian Ehrenfeld; Eva Lichtenegger; Marcel A Krüger; Klaus Mantwill; Florestan J Koll; Markus C Kowarik; Per Sonne Holm; Ulrike Naumann
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

7.  Demeclocycline Reduces the Growth of Human Brain Tumor-Initiating Cells: Direct Activity and Through Monocytes.

Authors:  Susobhan Sarkar; Yibo Li; Reza Mirzaei; Khalil S Rawji; Candice C Poon; Jianxiong Wang; Mehul Kumar; Pinaki Bose; V Wee Yong
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

8.  A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation.

Authors:  Jing Fu; Yaonan Li; Cuidan Li; Yuyang Tong; Mengyuan Li; Shundong Cang
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.